Seres Therapeutics Inc.
MCRB | NASDAQ
$4.07
$0 (0.00%)
Sep 22, 2026, 10:34 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 789K | n/a | n/a | n/a | 144.93M | 33.22M |
Cost of Revenue | 4.13M | 3.53M | 19.34M | n/a | n/a | 90.57M |
Gross Profit | -3.34M | -3.53M | -19.34M | n/a | 144.93M | -57.36M |
Operating Income | -93.97M | -121.32M | -195.1M | -179.91M | -64.49M | -88.13M |
Interest Income | 2.23M | 3.97M | 7.3M | 3.06M | 2.87M | 946K |
Pretax Income | 5.7M | -125.77M | -190.13M | -183.58M | -65.58M | -89.13M |
Net Income | 5.7M | -146.57M | -113.72M | -250.16M | -65.58M | -89.13M |
Selling & General & Admin | 39.16M | 53.18M | 77.5M | 70.26M | 69.26M | 30.78M |
Research & Development | 49.06M | 64.6M | 117.6M | 109.65M | 141.89M | 90.57M |
Other Expenses | 2.41M | n/a | -19.34M | n/a | -1.73M | -90.57M |
Operating Expenses | 90.63M | 117.78M | 175.76M | 179.91M | 209.42M | 30.78M |
Interest Expense | n/a | n/a | 13.18M | 6.02M | 2.91M | 2.92M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 94.76M | 121.32M | 195.1M | 179.91M | 209.42M | 121.35M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 8.86M | 7.77M | 6.4M | 5.4M | 4.59M | 3.99M |
Shares Outstanding (Diluted) | 8.87M | 7.77M | 6.4M | 5.4M | 4.59M | 3.99M |
EPS (Basic) | 0.64 | -18.86 | -17.77 | -46.29 | -14.30 | -22.34 |
EPS (Diluted) | 0.64 | -18.86 | -17.77 | -46.29 | -14.30 | -22.34 |
EBITDA | 9.83M | -120.3M | -181.42M | -170.93M | -56.72M | -77.31M |
EBIT | 5.7M | -125.77M | -187.66M | -177.56M | -62.67M | -86.2M |
Depreciation & Amortization | 4.13M | 5.47M | 6.24M | 6.63M | 5.95M | 8.89M |
Add to Watchlist
Select watchlists to add or remove MCRB